Metraipolis › archive › dc_8aaab560ca3a

First-in-human radiation dosimetry of the GRPR antagonist [68Ga]Ga-NOTA-PEG2-RM26 in patients with prostate and breast cancer — Europe PMC PMID:42310173

Source
Europe PMC (en)
Original
https://europepmc.org/article/MED/42310173
DOI
10.1186/s13550-[numero omesso]-2
License (as archived)
solo-consultazione
Archived
2026-10-19T08:11:56.181Z
SHA-256 of the archived text
eb5fe975daf67e67f7382f8a85345db1dffb0449a8970e7cf353b9f16ffbe6ad
Stable URL of this page
https://metraipolis.com/documento/dc_8aaab560ca3a

How to cite

First-in-human radiation dosimetry of the GRPR antagonist [68Ga]Ga-NOTA-PEG2-RM26 in patients with prostate and breast cancer — Europe PMC PMID:42310173 — Europe PMC (en), https://europepmc.org/article/MED/42310173 (solo-consultazione); archived copy: https://metraipolis.com/documento/dc_8aaab560ca3a (Metraipolis archive dc_8aaab560ca3a, sha256 eb5fe975daf67e67f7382f8a85345db1dffb0449a8970e7cf353b9f16ffbe6ad)
BibTeX
@misc{dc8aaab560ca3a,
  title = {First-in-human radiation dosimetry of the GRPR antagonist [68Ga]Ga-NOTA-PEG2-RM26 in patients with prostate and breast cancer — Europe PMC PMID:42310173},
  howpublished = {Europe PMC (en)},
  url = {https://europepmc.org/article/MED/42310173},
  note = {License solo-consultazione; archived copy https://metraipolis.com/documento/dc_8aaab560ca3a; sha256 eb5fe975daf67e67f7382f8a85345db1dffb0449a8970e7cf353b9f16ffbe6ad},
  year = {2026}
}

Archived text

The text is not reproduced here: the archive holds it as solo-consultazione (consultation only, no republication). Read it at the original source: https://europepmc.org/article/MED/42310173. Agents can read the archived copy with the MCP tool read_document.